Suppr超能文献

细胞外基质硬度对达格列净治疗糖尿病心肌病疗效的影响。

Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy.

机构信息

The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, P.R. China.

Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, 710049, P.R. China.

出版信息

Cardiovasc Diabetol. 2024 Jul 24;23(1):273. doi: 10.1186/s12933-024-02369-x.

Abstract

BACKGROUND

Extracellular matrix (ECM) stiffness is closely related to the progress of diabetic cardiomyopathy (DCM) and the response of treatment of DCM to anti-diabetic drugs. Dapagliflozin (Dapa) has been proven to have cardio-protective efficacy for diabetes and listed as the first-line drug to treat heart failure. But the regulatory relationship between ECM stiffness and treatment efficacy of Dapa remains elusive.

MATERIALS AND METHODS

This work investigated the effect of ECM stiffness on DCM progression and Dapa efficacy using both in vivo DCM rat model and in vitro myocardial cell model with high glucose injury. First, through DCM rat models with various levels of myocardial injury and administration with Dapa treatment for four weeks, the levels of myocardial injury, myocardial oxidative stress, expressions of ATR (a mechanical signal protein) and the stiffness of myocardial tissues were obtained. Then for mimicking the stiffness of myocardial tissues at early and late stages of DCM, we constructed cell models through culturing H9c2 myocardial cells on the polyacrylamide gels with two stiffness and exposed to a high glucose level and without/with Dapa intervention. The cell viability, reactive oxygen species (ROS) levels and expressions of mechanical signal sensitive proteins were obtained.

RESULTS

The DCM progression is accompanied by the increased myocardial tissue stiffness, which can synergistically exacerbate myocardial cell injury with high glucose. Dapa can improve the ECM stiffness-induced DCM progression and its efficacy on DCM is more pronounced on the soft ECM, which is related to the regulation pathway of ATR-FAK-NOX2. Besides, Dapa can inhibit the expression of the ECM-induced integrin β1, but without significant impact on piezo 1.

CONCLUSIONS

Our study found the regulation and effect of biomechanics in the DCM progression and on the Dapa efficacy on DCM, providing the new insights for the DCM treatment. Additionally, our work showed the better clinical prognosis of DCM under early Dapa intervention.

摘要

背景

细胞外基质(ECM)硬度与糖尿病心肌病(DCM)的进展以及 DCM 对糖尿病药物的治疗反应密切相关。达格列净(Dapa)已被证明对糖尿病具有心脏保护作用,并被列为治疗心力衰竭的一线药物。但 ECM 硬度与 Dapa 治疗效果之间的调节关系仍不清楚。

材料和方法

本研究通过体内 DCM 大鼠模型和高糖损伤体外心肌细胞模型,研究 ECM 硬度对 DCM 进展和 Dapa 疗效的影响。首先,通过不同心肌损伤程度的 DCM 大鼠模型,并给予 Dapa 治疗 4 周,检测心肌损伤水平、心肌氧化应激、ATR(机械信号蛋白)表达和心肌组织硬度。然后,为了模拟 DCM 早期和晚期心肌组织的硬度,我们通过在两种硬度的聚丙烯酰胺凝胶上培养 H9c2 心肌细胞,并暴露于高糖水平下,无/有 Dapa 干预,构建细胞模型。检测细胞活力、活性氧(ROS)水平和机械信号敏感蛋白的表达。

结果

DCM 进展伴随着心肌组织硬度的增加,这与高糖协同加重心肌细胞损伤。Dapa 可改善 ECM 硬度诱导的 DCM 进展,其对 DCM 的疗效在软 ECM 上更为明显,这与 ATR-FAK-NOX2 调节途径有关。此外,Dapa 可抑制 ECM 诱导的整合素 β1 的表达,但对 piezo 1 无明显影响。

结论

本研究发现了生物力学在 DCM 进展和 Dapa 对 DCM 疗效中的调节作用,为 DCM 治疗提供了新的见解。此外,我们的工作表明,早期 Dapa 干预可改善 DCM 的临床预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d139/11270890/382a34c6b759/12933_2024_2369_Sch1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验